{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-273633","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.067123+00:00","generated_at":"2026-06-08T09:07:21.777214+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics files $300M shelf, enters $100M ATM with Jefferies; terminates prior agreement","bullets":["Filed S-3 shelf registration for up to $300M of common, preferred, debt, warrants, and units.","Entered ATM offering agreement with Jefferies for up to $100M of common stock at market prices.","Jefferies will receive a 3% commission on gross proceeds from any ATM sales.","Prior ATM facility dated Nov 4, 2021 terminated and replaced by the new agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-273633","json":"https://secwatch.observer/filing/0001193125-23-273633.json","markdown":"https://secwatch.observer/filing/0001193125-23-273633.md","text":"https://secwatch.observer/filing/0001193125-23-273633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312523273633/0001193125-23-273633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312523273633/d554381d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:07:21.777214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1631a7e4faec276d86849bc151734b9677aa9f03","claim":"FATE THERAPEUTICS INC entered into Open Market Sale Agreement with Jefferies LLC valued at up to $100,000,000 (effective 2023-11-08).","evidence_excerpt":"on November 8, 2023, the Company entered into an Open Market Sale Agreement SM (the “Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Placement Shares”), through Jefferies as its sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312523273633/0001193125-23-273633-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"up to $100,000,000"},{"label":"Effective","value":"2023-11-08"}],"fact_type":"material_agreement"},{"claim_id":"426f1caa7cf6fbbacdeb4abc6308725287015dae","claim":"FATE THERAPEUTICS INC terminated Open Market Sale Agreement with Jefferies LLC (effective 2023-11-08).","evidence_excerpt":"Effective upon the execution of the Agreement, the Open Market Sale Agreement SM , dated November 4, 2021, by and between the Company and Jefferies (the “Prior Agreement”), was terminated and superseded by the Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312523273633/0001193125-23-273633-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Effective","value":"2023-11-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}